Shares of Alkermes Plc (NASDAQ:ALKS) have been assigned an average rating of “Hold” from the sixteen research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $37.55.

Several brokerages have issued reports on ALKS. HC Wainwright set a $25.00 price target on Epizyme and gave the company a “buy” rating in a research note on Friday, May 31st. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Citigroup upped their price target on Martin Marietta Materials from $239.00 to $255.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded Wix.Com from a “hold” rating to a “sell” rating in a report on Monday, April 8th. Finally, Credit Suisse Group set a $123.00 price target on Hershey and gave the stock a “hold” rating in a report on Friday, April 26th.

Shares of Alkermes stock traded up $1.34 during midday trading on Friday, reaching $24.43. The company had a trading volume of 76,700 shares, compared to its average volume of 1,404,061. The stock’s fifty day moving average is $22.52. The company has a current ratio of 2.94, a quick ratio of 2.65 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $3.64 billion, a price-to-earnings ratio of -348.14 and a beta of 1.83. Alkermes has a fifty-two week low of $21.29 and a fifty-two week high of $46.98.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, April 25th. The company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.06. The company had revenue of $223.10 million for the quarter, compared to analyst estimates of $218.84 million. Alkermes had a negative return on equity of 2.08% and a negative net margin of 15.86%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.09) earnings per share. Research analysts forecast that Alkermes will post -0.34 earnings per share for the current fiscal year.

In other Alkermes news, Director Richard F. Pops sold 110,000 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $24.88, for a total value of $2,736,800.00. Following the completion of the transaction, the director now owns 776,433 shares in the company, valued at approximately $19,317,653.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Richard F. Pops sold 60,000 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $25.42, for a total value of $1,525,200.00. Following the completion of the transaction, the chief executive officer now owns 776,433 shares of the company’s stock, valued at approximately $19,736,926.86. The disclosure for this sale can be found here. Insiders sold a total of 195,373 shares of company stock valued at $4,905,080 in the last 90 days. Corporate insiders own 4.71% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Clearbridge Investments LLC grew its stake in Alkermes by 0.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,275,948 shares of the company’s stock valued at $46,559,000 after purchasing an additional 9,979 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Alkermes by 37.2% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 593,706 shares of the company’s stock valued at $21,664,000 after purchasing an additional 160,930 shares during the period. Federated Investors Inc. PA grew its stake in Alkermes by 5.6% in the 1st quarter. Federated Investors Inc. PA now owns 257,376 shares of the company’s stock valued at $9,392,000 after purchasing an additional 13,608 shares during the period. NumerixS Investment Technologies Inc grew its stake in Alkermes by 15.5% in the 1st quarter. NumerixS Investment Technologies Inc now owns 8,910 shares of the company’s stock valued at $318,000 after purchasing an additional 1,198 shares during the period. Finally, Swiss National Bank grew its stake in Alkermes by 2.7% in the 1st quarter. Swiss National Bank now owns 518,200 shares of the company’s stock valued at $18,909,000 after purchasing an additional 13,400 shares during the period. Hedge funds and other institutional investors own 97.38% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Featured Story: Why are percentage gainers important?

Analyst Recommendations for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.